1 / 39

The recent big fluid trials

The recent big fluid trials. Sibylle A. Kozek-Langenecker M.D. Professor MBA Department of Anaesthesia and Intensive Care Evangelical Hospital Vienna www.perioperativebleeding.org sibylle.kozek@aon.at. Conflicts of interest. Honoraria for lectures and travel reimbursement: B. Braun

toya
Download Presentation

The recent big fluid trials

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The recent big fluid trials Sibylle A. Kozek-Langenecker M.D. Professor MBA Department of Anaesthesia and Intensive Care Evangelical Hospital Vienna www.perioperativebleeding.org sibylle.kozek@aon.at

  2. Conflicts of interest Honoraria for lectures and travel reimbursement: B. Braun Fresenius Kabi CSL Behring

  3. European Medicines Agency EMAPharmacovigilance Risk Assessment CommitteePRAC

  4. CMDh Statement: Information for healthcare professionals Because of the risk of kidney injury and mortality HES solutions must no longer be used in patients with sepsis, burn injuries or critically ill patients. HES solutions should only be used for the treatment of hypovolaemia due to blood loss when crystalloids alone are not considered sufficient. There is a lack of robust long-term safety data in patients undergoing surgical procedures and in patients with trauma. The expected benefit of treatment should be carefully weighed against the uncertainties with regard to long-term safety, and other available treatment options should be considered. Additional studies will be performed with HES solutions in patients with trauma and in elective surgery. HES solutions should be used at the lowest effective dose for the shortest period of time. Treatment should be guided by continuous haemodynamic monitoring so that the infusion is stopped as soon as appropriate haemodynamic goals have been achieved. HES solutions are now contraindicated in patients with renal impairment or renal replacement therapy. The use of HES must be discontinued at the first sign of renal injury. An increased need for renal replacement therapy has been reported up to 90 days after HES administration. Patients’ kidney function should be monitored after HES administration. HES solutions are contraindicated in severe coagulopathy. HES solutions should be discontinued at the first sign of coagulopathy. Blood coagulation parameters should be monitored carefully in case of repeated administration. CMDh: Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human

  5. Contraindications of HES 130 (after PRAC/CMDh 10/2013): Sepsis Burn trauma Renal insufficiency or RRT intracranial or cerebral bleeding Critical illness (on ICU) Hyperhydratation, incl. pulmonary edema Dehydratation Severe coagulopathy Severe liver dysfunction

  6. good drug kept in treatment repertoire medico-legal relevance of restrictions CI against initial volume resuscitation in sepsis irrational problem: „not bad drug but bad use of a drug“ problem: „only bad news are good news“ restrictions in surgery/trauma irrational & not practicable renal function 90 days postOP, severe coagulopathy … use of alternatives: less investigated/risky/expensive … Personal Interpretation

  7. Recent big fluid trials in critical illness

  8. Big trial in critical illness efficacy of initial colloidal volume therapy Annane. JAMA 2013;310:1809-17

  9. Results ? cause of death ? ? RRT-trigger ?

  10. CHEST: Statistical concerns J. Kreutziger, AIC 2013 X² Test p = 0.044 p = 0.054

  11. 6S: Statistical concerns J. Kreutziger, AIC 2013 X² Test p = 0.044 p = 0.054

  12. Randomisation AFTER initial stabilisation CHEST 6S NEJM 2012; 367;124-34 NEJM 2012;367:1901-11

  13. Recommendations against initial colloidal volume resuscitation cannot be derived from 6S, CHEST, VISEP

  14. ethics committee approval: use in known contraindication informed consent to use in known contraindication financial and intellectual conflicts of interest EMA: no data inspection before suspension/restriction NEJM, meta-analyses, Cochrane review: no concerns on ethics, methodological & statistical concerns Open questions

  15. Lesson learned from VISEP, CHEST and 6S:prolonged colloidal volume therapywithout indication according to preload a/o in the presence of contraindicationsmust be avoided

  16. ? infusion therapy with colloids only ? Not only 1 single magic bullet … ? surgery with muscle relaxant only ?

  17. „indiscriminate drug administration“ misuse, ban, prohibition … No indication for colloids • absence of intravascular hypovolaemia

  18. CHALLENGE of MONITORING intravascular filling status, microcirculation in organs, endothelial barrier function… Indication for colloids hypovolaemia with impaired tissue perfusion „goal-directed therapy (GDT)“ tailor drug administration in its indication

  19. Eur J Anaesthesiol 2013; 30: 270-382 http://esa.perioperativebleeding.org

  20. Avoid hypervolaemia We recommend avoiding hypervolemia with crystalloids or colloids to a level exceeding the interstitial space in steady state, and beyond an optimal cardiac preload 1B Eur J Anaesthesiol 2013; 30: 270-382

  21. Preload optimization We recommend aggressive and timely stabilisation of cardiac preload throughout the surgical procedure, as this appears beneficial to the patient 1B Eur J Anaesthesiol 2013; 30: 270-382

  22. Tissue perfusion We recommend repeated measurements of a combination of Hk/Hb, serum lactate, and base deficit in order to monitor tissue perfusion, tissue oxygenation and the dynamics of blood loss during acute bleeding. These parameters can be extended by measurement of cardiac output, dynamic parameters of volume status (e.g. SVV, PPV) and central venous saturation 1C Eur J Anaesthesiol 2013; 30: 270-382

  23. Monitoring MAP, CVP, HR:Crystalloid:colloid ratioscannot be derived from 6S, CHEST, VISEP

  24. Systematic reviews and meta-analyses: pooling of study limitationsnot helpful Zarychanski R. JAMA. 2013;309(7):678-688 Patel A. Intensive Care Med 2013; DOI 10.1007/s00134-013-2863-6 Haase N. BMJ 2013;346:f839 doi: 10.1136/bmj.f839 …

  25. EVIDENCE from Cochrane Analyses 2013:„… hard to see how the use of colloids can be justified …“

  26. „… no evidence that one colloid solution is more effictive or safe than any other…“

  27. „… hard to see how the use of albumin can be justified …“

  28. Crit Care 2013; 17: R166

  29. The FIRST Study: Lactate clearance Fluids In Resuscitationin Severe Trauma • similar static hemodynamic measurements between groups • superior tissue perfusion after HES compared to saline James. Br J Anaesth 2011;107:693

  30. CI, cardiac indexCVP central venous pressure SVV, stroke volume variation PEEP, positive end-expiratory pressureVt, tidal volume Benes. Crit Care 2010;14;R118

  31. GDT: improved tissue perfusion Benes. Crit Care 2010;14;R118

  32. GDT: less complications Benes. Crit Care 2010;14;R118

  33. Big trial in elective surgery colloidal volume therapy & patient safety n = 4.529 Van der Linden. Anaesth Analg 2013;116:35-48

  34. Big trial in elective surgery colloidal volume therapy & renal function Martin. Anesthesiology 2013; 118: 387-94 n = 1.230 in 17 studies n = 1.230 in 17 studies serum creatinine extreme values risk difference acute renal failure

  35. …….. Coriat, Guidet, de Hert, Kochs, Kozek, van Aken 71 co-signatories …….. Coriat, Guidet, de Hert, Kochs, Kozek, van Aken 71 co-signatories

  36. Alternatives? Perfusion monitoring?

  37. Thank you for your attention ! www.perioperativebleeding.org sibylle.kozek@aon.at

More Related